Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 503

1.

Effects of dual modified resistant indica rice starch on azoxymethane-induced incipient colon cancer in mice.

Yuan H, Zhu X, Chen D, Wang W, Meng S, Wang J.

Exp Ther Med. 2017 May;13(5):2036-2042. doi: 10.3892/etm.2017.4172. Epub 2017 Mar 2.

2.

Increased risk for diabetes development in subjects with large variation in total cholesterol levels in 2,827,950 Koreans: A nationwide population-based study.

Rhee EJ, Han K, Ko SH, Ko KS, Lee WY.

PLoS One. 2017 May 18;12(5):e0176615. doi: 10.1371/journal.pone.0176615. eCollection 2017.

4.

Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.

Gale R, Scanlon PH, Evans M, Ghanchi F, Yang Y, Silvestri G, Freeman M, Maisey A, Napier J.

Eye (Lond). 2017 May;31(S1):S1-S20. doi: 10.1038/eye.2017.53.

5.

Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus.

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S.

Circulation. 2017 Apr 18;135(16):1522-1531. doi: 10.1161/CIRCULATIONAHA.116.025961. Epub 2017 Feb 22.

6.

Efficacy of Administration of an Angiotensin Converting Enzyme Inhibitor for Two Years on Autonomic and Peripheral Neuropathy in Patients with Diabetes Mellitus.

Didangelos T, Tziomalos K, Margaritidis C, Kontoninas Z, Stergiou I, Tsotoulidis S, Karlafti E, Mourouglakis A, Hatzitolios AI.

J Diabetes Res. 2017;2017:6719239. doi: 10.1155/2017/6719239. Epub 2017 Mar 8.

7.

Poor uptake of an online intervention in a cluster randomised controlled trial of online diabetes education for rural general practitioners.

Paul CL, Piterman L, Shaw JE, Kirby C, Forshaw KL, Robinson J, Thepwongsa I, Sanson-Fisher RW.

Trials. 2017 Mar 23;18(1):137. doi: 10.1186/s13063-017-1869-8.

8.

New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain.

Feldman EL, Nave KA, Jensen TS, Bennett DL.

Neuron. 2017 Mar 22;93(6):1296-1313. doi: 10.1016/j.neuron.2017.02.005. Review.

PMID:
28334605
9.

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.

Courtney H, Nayar R, Rajeswaran C, Jandhyala R.

Diabetes Metab Syndr Obes. 2017 Mar 13;10:79-87. doi: 10.2147/DMSO.S126763. eCollection 2017. Review.

10.
11.

Effectiveness of Integrated Care on Delaying Progression of stage 3-4 Chronic Kidney Disease in Rural Communities of Thailand (ESCORT study): a cluster randomized controlled trial.

Jiamjariyapon T, Ingsathit A, Pongpirul K, Vipattawat K, Kanchanakorn S, Saetie A, Kanistanon D, Wongprompitak P, Leesmidt V, Watcharasaksilp W, Wang W, Chandraker AK, Tungsanga K.

BMC Nephrol. 2017 Mar 2;18(1):83. doi: 10.1186/s12882-016-0414-4.

12.

Comparative study of cardiac autonomic status by heart rate variability between under-treatment normotensive and hypertensive known type 2 diabetics.

Solanki JD, Basida SD, Mehta HB, Panjwani SJ, Gadhavi BP.

Indian Heart J. 2017 Jan - Feb;69(1):52-56. doi: 10.1016/j.ihj.2016.07.013. Epub 2016 Aug 2.

13.

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.

Mezquita-Raya P, Ramírez de Arellano A, Kragh N, Vega-Hernandez G, Pöhlmann J, Valentine WJ, Hunt B.

Diabetes Ther. 2017 Apr;8(2):401-415. doi: 10.1007/s13300-017-0239-6. Epub 2017 Feb 21.

14.

Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.

Hunt B, Ye Q, Valentine WJ, Ashley D.

Diabetes Ther. 2017 Feb;8(1):129-147. doi: 10.1007/s13300-016-0219-2. Epub 2017 Jan 5.

15.

New therapeutic agents in diabetic nephropathy.

Kim Y, Park CW.

Korean J Intern Med. 2017 Jan;32(1):11-25. doi: 10.3904/kjim.2016.174. Epub 2017 Jan 1. Review.

16.

Time-saving screening for diabetes in patients with coronary artery disease: a report from EUROASPIRE IV.

Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O, Tuomilehto J, Wood D, Rydén L.

BMJ Open. 2016 Dec 8;6(12):e013835. doi: 10.1136/bmjopen-2016-013835.

17.

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T.

PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125. eCollection 2016.

18.

Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology.

Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, Gulati M, Masoudi FA, Goff DC Jr.

J Am Coll Cardiol. 2017 Mar 28;69(12):1617-1636. doi: 10.1016/j.jacc.2016.10.018. Epub 2016 Nov 4.

PMID:
27825770
19.

Vejle Diabetes Biobank - a resource for studies of the etiologies of diabetes and its comorbidities.

Petersen ER, Nielsen AA, Christensen H, Hansen T, Pedersen O, Christensen CK, Brandslund I.

Clin Epidemiol. 2016 Oct 21;8:393-413. eCollection 2016.

20.

Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease.

Zonszein J, Groop PH.

Diabetes Ther. 2016 Dec;7(4):621-639. Epub 2016 Oct 31. Review.

Supplemental Content

Support Center